Akebia Therapeutics Signs A Multi-Year Commercial Contract With One Of The Nation's Leading Providers Of Kidney Care Services, Expanding Access To Vafseo For Patients On Dialysis; The Contract Enables Physicians To Prescribe Vafseo To Patients On...
Akebia Therapeutics Signs A Multi-Year Commercial Contract With One Of The Nation's Leading Providers Of Kidney Care Services, Expanding Access To Vafseo For Patients On Dialysis; The Contract Enables Physicians To Prescribe Vafseo To Patients On...
Akebia Therapeutics Signs A Multi-Year Commercial Contract With One Of The Nation's Leading Providers Of Kidney Care Services, Expanding Access To Vafseo For Patients On Dialysis; The Contract Enables Physicians To Prescribe Vafseo To Patients On Dialysis As Deemed Clinically Appropriate;' Akebia Expects Vafseo Will Be Available In The U.S. In January 2025.
akebia therapeutics與全國領先的腎臟護理服務提供商簽訂了一項多年的商業合同，擴大了透析患者對Vafseo的獲取；該合同使醫生可以根據臨床判斷爲透析患者開具Vafseo處方；Akebia預計Vafseo將於2025年1月在美國上市。
Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers
與一家綜合腎臟護理服務提供商簽訂了合同，在其數千家美國透析中心爲超過20萬患者提供服務。
CAMBRIDGE, Mass., Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services, expanding access to Vafseo (vadadustat) for patients on dialysis. The contract enables physicians to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia expects Vafseo will be available in the U.S. in January 2025.
馬薩諸塞州劍橋，2024年10月22日 / PR Newswire / - akebia therapeutics, Inc. (納斯達克: AKBA)是一家生物製藥公司，旨在改善受腎病影響的人們的生活，今天宣佈已與全國領先的腎臟護理服務提供商簽訂了一項多年的商業合同，擴大了透析患者對Vafseo（vadadustat）的獲取；該合同使醫生可以根據臨床判斷爲透析患者開具Vafseo處方；Akebia預計Vafseo將於2025年1月在美國上市。
譯文內容由第三人軟體翻譯。
